Authors

Latest:

Research Findings Point to Clinical Importance of Clonal Hematopoiesis

Although clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.

Peter J Sciavolino, PhD

Latest:

Distinct Genomic Differences Evident in Younger Patients With Lung Cancer

Clinical trial findings have implications for expanding the use of genomic testingâ€”and thereby potentially increasing treatment optionsâ€”for the younger lung cancer population.

Peter J. Van Veldhuizen, MD

Latest:

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

Peter Krein, PhD

Latest:

Peter Krein on Developments in Liquid Biopsies

Peter Krein, PhD, senior director, Medical and Scientific Affairs, QIAGEN, discusses the company's latest advancements in liquid biopsies in comparison to surgical biopsies.

Peter L. Choyke, MD

Latest:

Dr. Choyke on Advancements in Imaging for Prostate Cancer

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses advances in imaging for prostate cancer.

Peter L. Choyke, MD, FACP

Latest:

Dr. Choyke on Differences Between PET Scans in Prostate Cancer

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the differences between PET scans in prostate cancer.

Peter L. Salgo, MD, NewYork-Presbyterian Hospital

Peter Langmuir, MD

Latest:

Dr. Langmuir Explains the Side Effects of Vandetanib

Peter Levonian, MS

Latest:

Potential Risks of Genetic Testing in Ovarian Cancer

Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the potential risks of genetic testing in ovarian cancer.

Peter Martin, MD

Latest:

Dr Martin on the Role of BTK Inhibitors in the Management of MCL

Peter Martin, MD, discusses the role of BTK inhibitors in the treatment of mantle cell lymphoma.

Peter Martin, MD, MS, Weill Cornell Medicine

Peter Martin, MD, Weill Cornell Medicine

Peter O'Donnell, MD

Latest:

Dr. O'Donnell on Challenges With PD-L1 Testing in Bladder Cancer

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses challenges with PD-L1 testing in patients with bladder cancer.

Peter R. Carroll, MD

Latest:

Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate Cancer

Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.

Peter R. Dottino, MD

Latest:

Dr. Dottino on the Benefit of Early-Detection Screening in Endometrial Cancer

Peter R. Dottino, MD, discusses the benefit of early-detection screening for endometrial cancer.

Peter R. Galle, MD, PhD, Mainz University Medical Center

Latest:

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.

Peter Schmid, MD

Latest:

Dr. Schmid on Activity With Neoadjuvant Pembrolizumab in TNBC

Peter Schmid, MD, PhD, discusses the benefit of pembrolizumab when added to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Peter Schmid, MD, PhD

Latest:

Dr Schmid on Pembrolizumab Plus Chemotherapy in High-Risk, Early-Stage TNBC

Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.

Peter Soyer, MD

Latest:

Dr. Soyer Discusses the Role of Technology in Melanoma

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses the role of technology in melanoma.

Peter Voorhees, MD, Atrium Health

Latest:

Dr. Voorhees on the Utilization of Proteasome Inhibitors for Newly Diagnosed Multiple Myeloma

Peter Voorhees, MD, discusses developments in the efficacy and application of proteasome inhibitors for patients with newly diagnosed multiple myeloma.